TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner Advancing felzartamab – a CD38-directed antibody with potential broad applicability...